Building on our previous preclinical study [9], we have developed unique loop bispecific CAR-T cells that target CD19 and CD22 (CD19/CD22 BS Loop CAR), and we present herein the treatment outcomes for five adult patients with r/r DLBCL. Here, CD19 is linked to diffuse large B-cell lymphoma.